E
Rani Therapeutics Holdings, Inc. RANI
$1.10 -$0.02-1.79% NASDAQ
Recommendation
Prev Close
$1.10
Volume
9,022
Avg Vol (90D)
716,200
Market Cap
$36.86M
Dividend & Yield
--
52-Week Range
$1.02 - $7.88
P/E (TTM)
--
EPS (TTM)
-$1.06
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Buy" from Analysts
4/26/2025 - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Buy" from Analysts
4/24/2025 - Ticker Report
Brokerages Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $12.33
4/6/2025 - Ticker Report
What is Zacks Small Cap's Estimate for RANI FY2025 Earnings?
4/5/2025 - MarketBeat
Rani Therapeutics (NASDAQ:RANI) Earns "Buy" Rating from HC Wainwright
4/5/2025 - MarketBeat
Rani Therapeutics (NASDAQ:RANI) Releases Earnings Results, Misses Estimates By $0.03 EPS
4/2/2025 - MarketBeat
Rani Therapeutics (NASDAQ:RANI) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
4/2/2025 - MarketBeat
Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ...
4/1/2025 - GuruFocus
Q4 2024 Rani Therapeutics Holdings Inc Earnings Call Transcript
4/1/2025 - GuruFocus
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
3/31/2025 - Seeking Alpha: Transcripts
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
3/31/2025 - SeekingAlpha
Rani Therapeutics Holdings, Inc. 2024 Q4 - Results - Earnings Call Presentation
3/31/2025 - SeekingAlpha
Rani Therapeutics Holdings Inc Reports Q4 2024 Earnings: EPS Misses at -$0. ...
3/31/2025 - GuruFocus
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
3/31/2025 - Globe Newswire
Takeda Pharmaceutical Co. Ltd. Buys Shares of 203,190 Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)
3/28/2025 - MarketBeat
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill Capsule, to Subcutaneously Administered PG-102
3/26/2025 - Globe Newswire
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
3/25/2025 - Globe Newswire
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by Analysts
3/5/2025 - Ticker Report
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Large Increase in Short Interest
3/5/2025 - MarketBeat
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Rani Therapeutics Holdings (RANI)
3/1/2025 - TipRanks Financial Blog
Is Rani Therapeutics Holdings (NASDAQ:RANI) Using Too Much Debt?
2/7/2025 - Simply Wall St
Rani Therapeutics (NASDAQ:RANI) Stock Price Up 0.7% - Here's Why
2/6/2025 - MarketBeat
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill HC
2/5/2025 - Globe Newswire
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $11.71 Average Price Target from Analysts
1/17/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$1.03M
EBITDA (TTM)
-$48.57M
EBIT (TTM)
-$49.60M
Net Income (TTM)
-$30.02M
Balance Sheet
Total Assets (Q)
$36.63M
Total Debt (Q)
$29.71M
Total Liabilities (Q)
$33.14M
Book Value Per Share (Q)
$0.0596
Cash Flow
Cash from Operations (TTM)
-$35.50M
Cash from Investing (TTM)
$19.81M
Cash from Financing (TTM)
$13.59M
Net Change in Cash (TTM)
-$2.10M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.09
7-Day Total Return
-5.98%
30-Day Total Return
-28.57%
60-Day Total Return
-20.86%
90-Day Total Return
-30.82%
Year to Date Total Return
-24.66%
1-Year Total Return
-83.58%
2-Year Total Return
-76.89%
3-Year Total Return
-91.01%
5-Year Total Return
--
52-week Low
Apr 25, 2025 - $1.02
52-week High
May 07, 2024 - $7.88
Valuation
Market Cap
$36.86M - Nano Cap
Enterprise Value
$40.43M
Price/Sales (TTM)
35.03
Price/Book (Q)
18.46
Dividends and Shares
Shares Outstanding
32.66M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ranitherapeutics.com
Phone Number
408 457 3700
Address
2051 Ringwood Avenue
San Jose, CA 95131
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients... more
NASDAQ 04/28/2025 4:00PM Eastern Quotes delayed